Search Within

Omar Ibrahim Abdel-Wahab

  1. "Biostatistics Service"
Formats
  1. Journal Article (31)
  2. Meeting Abstract (19)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (51)
  2. Center for Hematologic Malignancies (51)
  3. Department of Medicine (51)
  4. Epidemiology and Biostatistics (51)
  5. Executive Committee, Center for Hematologic Malignancies (51)
  6. GSK Faculty (51)

More Groups

People
  1. Ross Levine (28)
  2. Martin Tallman (24)
  3. Mithat Gonen (21)
  4. Eytan Stein (12)
  5. Andriy Derkach (10)
  6. Ahmet Dogan (9)

More People

Years
  1. 2024 (1)
  2. 2023 (9)
  3. 2022 (4)
  4. 2021 (4)
  5. 2020 (4)
  6. 2019 (4)

More Years

Publications
  1. Blood (18)
  2. British Journal of Haematology (4)
  3. Blood Advances (3)
  4. Leukemia (3)
  5. Leukemia Research (2)
  6. Nature (2)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Nature Publishing Group (9)
  3. John Wiley & Sons (4)
  4. Elsevier Science, Inc. (3)
  5. Massachusetts Medical Society (3)
  6. Elsevier Inc. (2)

More Publishers

Results (51)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
    Journal Article

    Handa, S.; Lee, J. O.; Derkach, A.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Shukla, M.; Vemuri, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
    Journal Article

    Ganzel, C.; Sun, Z.; Baslan, T.; Zhang, Y.; Gönen, M.; Abdel-Wahab, O. I.; Racevskis, J.; Garrett-Bakelman, F.; Lowe, S. W.; Fernandez, H. F.; more...
    Leukemia Research (2022)

    Fulltext@MSK | Save
  • Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
    Journal Article

    Chowell, D.; Yoo, S. K.; Valero, C.; Pastore, A.; Krishna, C.; Lee, M.; Hoen, D.; Shi, H.; Kelly, D. W.; Patel, N.; more...
    Nature Biotechnology (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
    Journal Article

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J.; King, A. C.; Daniyan, A. F.; Famulare, C.; Cuello, B. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save